Saltar al contenido
Merck

PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding.

The Journal of biological chemistry (2021-04-09)
Alberto Carpinteiro Soares, Andreia Ferreira, Jonas Mariën, Charlotte Delay, Edward Lee, John Q Trojanowski, Dieder Moechars, Wim Annaert, Louis De Muynck
RESUMEN

Tauopathies, such as Alzheimer's disease (AD), are neurodegenerative disorders characterized by the deposition of hyperphosphorylated tau aggregates. Proteopathic tau seeds spread through the brain in a temporospatial pattern, indicative of transsynaptic propagation. It is hypothesized that reducing the uptake of tau seeds and subsequent induction of tau aggregation could be a potential approach for abrogating disease progression in AD. Here, we studied to what extent different endosomal routes play a role in the neuronal uptake of preformed tau seeds. Using pharmacological and genetic tools, we identified dynamin-1, actin, and Rac1 as key players. Furthermore, inhibition of PIKfyve, a protein downstream of Rac1, reduced both the trafficking of tau seeds into lysosomes and the induction of tau aggregation. Our work shows that tau aggregates are internalized by a specific endocytic mechanism and that their fate once internalized can be pharmacologically modulated to reduce tau seeding in neurons.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Suero de cabra
Sigma-Aldrich
Rac1 Inhibitor, Rac1 Inhibitor, CAS 1177865-17-6, is a cell-permeable, reversible inhibitor of Rac1 GDP/GTP exchange. Interferes with the interaction between Rac1 and Rac-specific GEFs Trio and Tiam1 (IC₅₀ ~50 µM).
Sigma-Aldrich
Anti-Tau Antibody, clone T49 (Not human), clone T49, from mouse
Sigma-Aldrich
Anti-Rac1 Antibody, clone 23A8, clone 23A8, Upstate®, from mouse